DGAP-News

WILEX AG: WILEX enters into licensing and development partnership for MESUPRON(R) in China with Link Health Group

DGAP-News: WILEX AG / Key word(s): Alliance
WILEX AG: WILEX enters into licensing and development partnership for
MESUPRON(R) in China with Link Health Group

28.03.2014 / 17:25

---------------------------------------------------------------------

PRESS RELEASE

WILEX enters into licensing and development partnership for MESUPRON(R) in
China with Link Health Group

- WILEX will receive milestone payments for clinical development and
regulatory approval as well as royalty payments

- Link Health will be responsible for all development activities and the
regulatory process for MESUPRON(R)

Munich, Germany / Guangzhou, China, 28 March 2014 - WILEX AG (ISIN
DE0006614720 / WL6 / FSE) today announced that it has entered into a
licensing and development partnership for MESUPRON(R) with Link Health Co.,
Guangzhou, China. Link Health will receive the exclusive licensing rights
for the development and marketing of MESUPRON(R) in China, Hong Kong,
Taiwan and Macao.

Link Health will be responsible for performing and financing the entire
clinical development of MESUPRON(R) in China in all oncological
indications, including HER2-negative metastatic breast cancer and
non-metastatic pancreatic cancer, as well as for the regulatory process and
product marketing. To receive regulatory approval from the SFDA (Chinese
State Food and Drug Administration), the complete clinical development
programme from Phase I to Phase III must also be conducted in China, one of
the largest pharmaceutical markets with rapid growth rates. The data
generated may be used to support potential further development of
MESUPRON(R) in other key markets.

Under the agreement, WILEX will receive a signing fee and milestone
payments totalling more than 7 million Euro during clinical development in
the first four indications to be developed by Link Health as well as
staggered medium single digit royalties. The initial fees received by WILEX
under the cooperation will not materially influence the current cash reach
of the company.

Prof Olaf G. Wilhelm, CEO of WILEX AG, commented: "Signing the contract
with Link Health today is a very important step for us because it means
that we will be able to further advance the development of MESUPRON(R) in
one of Asia's principal markets with an expert partner. Link Health not
only has development expertise but also possesses know-how in connection
with regulatory approval and the marketing of oncology products. For us, it
is a first step, and we will work in parallel on further licensing
options."

Dr Wang, CEO of the Link Health Group, said: "We are proud to be given the
opportunity to take over this innovative product for our region and are